Tokyo Metropolitan Komagome Hospital
Vinorelbine monotherapy used in advanced or recurrent breast cancer
Published in Women's Health Law Weekly, September 25th, 2005
"At present, it is one of the most important issues for the treatment of breast cancer to develop the standard therapy for patients previously treated with anthracyclines and taxanes. With the objective of determining the usefulness of vinorelbine monotherapy in patients with advanced or recurrent breast cancer after standard therapy, we evaluated the efficacy and safety of vinorelbine in patients previously treated with anthracyclines and taxanes," scientists in Japan reported.
"Vinorelbine was administered at a dose...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
More Articles from Women's Health Law Weekly
- Areteion Hospital, Athens
Approaches to managing bone metastases from breast cancer shared - Hologic
Alliance signed with Novation for mammography, bone densitometry systems - Remuda Ranch
As eating disorders increase in colleges, more schools offer counseling - VA Ann Arbor Healthcare System
Attitudes about perception of risk shift after breast cancer counseling - Aichi Medical University School of Medicine
Breast cancer risk, alcohol intake in Japanese women studied - Albert Einstein College of Medicine
Further research needed on HIV in an aging population - More from this issue of Women's Health Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
